ATE388165T1 - Menschliches cnp-gen und vorläuferprotein - Google Patents

Menschliches cnp-gen und vorläuferprotein

Info

Publication number
ATE388165T1
ATE388165T1 AT96114549T AT96114549T ATE388165T1 AT E388165 T1 ATE388165 T1 AT E388165T1 AT 96114549 T AT96114549 T AT 96114549T AT 96114549 T AT96114549 T AT 96114549T AT E388165 T1 ATE388165 T1 AT E388165T1
Authority
AT
Austria
Prior art keywords
precussion
protein
human cnp
human
cnp gene
Prior art date
Application number
AT96114549T
Other languages
English (en)
Inventor
Shoji Tanaka
Kayoko Kawashima
Yasunori Tawaragi
Hisayuki Matsuo
Kenji Kangawa
Naoto Minamino
Original Assignee
Asubio Pharma Co Ltd
Hisayuki Matsuo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asubio Pharma Co Ltd, Hisayuki Matsuo filed Critical Asubio Pharma Co Ltd
Application granted granted Critical
Publication of ATE388165T1 publication Critical patent/ATE388165T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96114549T 1990-09-27 1991-09-27 Menschliches cnp-gen und vorläuferprotein ATE388165T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP02259698A JP3026354B2 (ja) 1990-09-27 1990-09-27 ヒトcnp遺伝子及び前駆体蛋白

Publications (1)

Publication Number Publication Date
ATE388165T1 true ATE388165T1 (de) 2008-03-15

Family

ID=17337688

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96114549T ATE388165T1 (de) 1990-09-27 1991-09-27 Menschliches cnp-gen und vorläuferprotein
AT91116557T ATE162532T1 (de) 1990-09-27 1991-09-27 Merschliches cnp-gen und vorläufer protein

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT91116557T ATE162532T1 (de) 1990-09-27 1991-09-27 Merschliches cnp-gen und vorläufer protein

Country Status (8)

Country Link
US (1) US6034231A (de)
EP (2) EP0477971B1 (de)
JP (1) JP3026354B2 (de)
AT (2) ATE388165T1 (de)
DE (2) DE69133593T2 (de)
DK (1) DK0477971T3 (de)
ES (2) ES2113865T3 (de)
GR (1) GR3026554T3 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
SG159387A1 (en) 2002-11-26 2010-03-30 Biocon Ltd In Modified natriuretic compounds, conjugates, and uses thereof
ES2465141T3 (es) * 2004-03-31 2014-06-05 Kazuwa Nakao Remedio o medicamento preventivo para la artritis
KR20070007842A (ko) 2004-03-31 2007-01-16 카즈와 나카오 신장증가용 조성물
PL1759001T3 (pl) 2004-04-21 2011-09-30 Alexion Pharma Inc Koniugaty dostarczane do kości i sposób ich zastosowania do nakierowywania białek do kości
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
WO2007061715A2 (en) * 2005-11-18 2007-05-31 The Brigham & Women's Hospital, Inc. Detection, generation and uses of atherosclerosis-protective vascular endothelium
AR069409A1 (es) * 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
PT2277890E (pt) * 2008-05-23 2016-03-31 Daiichi Sankyo Co Ltd Péptido capaz de prolongar o semi-período de vida do péptido de interesse no plasma
EP2432489B1 (de) 2009-05-20 2016-10-05 BioMarin Pharmaceutical Inc. Varianten des natriuretischen peptids typ c
JP6055779B2 (ja) 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ, インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法
KR20140084201A (ko) 2011-10-19 2014-07-04 알렉시온 파마 홀딩 알칼리성 포스파타제 및/또는 나트륨이뇨 펩티드를 포함하는 조성물 및 그의 사용 방법
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
JP6787894B2 (ja) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ, インコーポレイテッド 組換えアルカリホスファターゼを用いた発作の処置
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
PT3328416T (pt) 2015-07-30 2024-04-10 Biomarin Pharm Inc Utilização de variantes do péptido natriurético de tipo c para tratar as displasias esqueléticas
JP6993961B2 (ja) 2015-08-17 2022-01-14 アレクシオン ファーマシューティカルズ, インコーポレイテッド アルカリホスファターゼの製造
EP3355904A4 (de) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. Identifizierung wirksamer dosierungsschemata für gewebeunspezifische alkalische phosphatase-enzymersatztherapie von hypophosphatasie
EP3368062A4 (de) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von craniosynostose bei einem patienten
EP4710947A3 (de) 2016-01-08 2026-06-17 Ascendis Pharma Growth Disorders A/S Cnp-agonisten mit kontrollierter freisetzung mit reduzierten nebenwirkungen
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
KR20180125979A (ko) 2016-04-01 2018-11-26 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ, インコーポレイテッド 気管気管支軟化症の治療方法
RU2768747C2 (ru) 2016-09-29 2022-03-24 Асцендис Фарма Гроус Дизордерс А/С Комбинаторная терапия с агонистами cnp контролируемого высвобождения
KR20190129058A (ko) 2017-03-31 2019-11-19 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
MX2022003184A (es) 2019-09-16 2022-06-23 Biomarin Pharm Inc Variantes del cnp y sus conjugados.
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
US12611447B2 (en) 2020-09-04 2026-04-28 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
AU2022218782B2 (en) 2021-02-12 2026-06-25 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
MX2024000526A (es) 2021-07-09 2024-02-02 Biomarin Pharm Inc Variantes del peptido natriuretico tipo c para tratar la displasia esqueletica en ni?os.
CA3242257A1 (en) 2021-12-07 2023-06-15 Biomarin Pharmaceutical Inc. C-type natriuretic peptide therapy of bone-related disorders
KR102866559B1 (ko) 2022-11-02 2025-10-02 노보 노르디스크 에이/에스 Cnp 화합물
WO2024254405A2 (en) 2023-06-07 2024-12-12 Biomarin Pharmaceutical Inc. High throughput screen for genetic variants associated with short stature
IL328265A (en) 2023-11-08 2026-07-01 Biomarin Pharm Inc CNP variants, conjugates and their formulations
WO2026030743A1 (en) 2024-08-02 2026-02-05 Biomarin Pharmaceutical Inc. Treatment of short stature with cnp variants

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339210C (en) * 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides

Also Published As

Publication number Publication date
EP0477971A2 (de) 1992-04-01
GR3026554T3 (en) 1998-07-31
DE69128754T2 (de) 1998-06-04
EP0769554B1 (de) 2008-03-05
JP3026354B2 (ja) 2000-03-27
EP0769554A3 (de) 1997-05-28
DE69133593T2 (de) 2009-04-02
DK0477971T3 (da) 1998-09-21
EP0769554A2 (de) 1997-04-23
ES2302333T3 (es) 2008-07-01
JPH04139199A (ja) 1992-05-13
DE69128754D1 (de) 1998-02-26
ATE162532T1 (de) 1998-02-15
EP0477971B1 (de) 1998-01-21
EP0477971A3 (en) 1992-09-09
ES2113865T3 (es) 1998-05-16
DE69133593D1 (de) 2008-04-17
US6034231A (en) 2000-03-07

Similar Documents

Publication Publication Date Title
DE69133593D1 (de) Menschliches CNP-Gen und Vorläuferprotein
IL131016A0 (en) Selection of proteins using rna-protein fusions
AU631681B2 (en) Radiolabeled anticoagulant peptides
DE69131699D1 (de) Verändertes menschliches iL-6
DE3672924D1 (de) Cystein verminderte muteine von biologisch aktiven menschlichen tnf-proteinen.
ATE182901T1 (de) Für androgen-rezeptor-protein kodierende dna
ES2153037T3 (es) Lacasas purificadas de scytalidium y acidos nucleicos que las codifican.
NO971875L (no) Cathepsin 02 protease
ES2184728T3 (es) Proteinas de union a la fibronectina.
FI962247A7 (fi) Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden kä yttömenetelmät
FI885504A0 (fi) Vaskulaera antikoagulerande proteiner, dessa koderande dna, deras framstaellningsfoerfarande och deras anvaendning.
ES548617A0 (es) Procedimiento para disociar peptidos y proteinas en el enla-ce metionilo
FI90667C (fi) Menetelmä valmistaa uutta ihmisen tyypin I interferoniproteiinia
ZA907742B (en) Anticoagulant peptides
ES2146193T1 (es) Proteinas del virus del arrugado de las hojas de la vid (tipo 2) y sus usos.
DE69328060D1 (de) Angiotensin-II Typ-1 Rezeptor und dessen Herstellung
ZA899247B (en) Anticoagulant peptides
EP0677115A4 (de) Tia-1 bindendes protein und dafür kodierende, isolierte und komplementäre dna.
EP0723016A3 (de) Leukocyten-aktivierender Faktor
EP0676413A3 (de) Interferon alpha/beta bindendes Protein, seine Herstellung und Anwendung.
AU8957091A (en) Immunoglobulin-binding proteins and recombinant dna molecules coding therefor
DE59109235D1 (de) Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung
ES2059801T3 (es) Nuevas linfoquinas, secuencias de adn que codifican para estas linfoquinas, y composiciones farmaceuticas conteniendo estas linfoquinas.
FI885301A7 (fi) Tekijä VIII:n puhdistuksessa käyttökelpoisia peptidejä
ATE75255T1 (de) Peptid und dafuer kodierendes gen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties